our clinical trials

Pharvaris aims to bring better oral options to meet the needs of people with HAE for on-demand and prophylactic treatment. We are developing novel, potent and selective B2-receptor antagonist small molecules for the treatment of all sub-types of HAE.

 

HAE CHAPTER-1

Oral prophylactic treatment study

    • For whom – people diagnosed with hereditary angioedema (HAE).
    • Purpose – to evaluate PHVS416 in preventing HAE attacks.
    • Approach – soft capsules taken orally to prevent HAE attacks

    For more information, visit haechapter-1.com or https://clinicaltrials.gov/show/NCT05047185.

    * The FDA has placed a clinical hold on the clinical trials of PHA121 in the U.S.

     RAPIDe-2

    Extension study of oral on-demand treatment

      • For whom – people diagnosed with hereditary angioedema (HAE) who participated in RAPIDe-1
      • Purpose – To further assess safety and efficacy of PHVS416 is in relieving symptoms associated with HAE attacks with long-term dosing.
      • Approach – soft capsules taken orally to prevent HAE attacks

      For more information, visit  https://clinicaltrials.gov/ct2/show/NCT05396105

      * The FDA has placed a clinical hold on the clinical trials of PHA121 in the U.S.

       RAPIDe-1

      Oral on-demand treatment study

      • For whom – people diagnosed with hereditary angioedema (HAE).
      • Purpose – To find out how effective PHVS416 is in relieving symptoms associated with HAE attacks.
      • Approach – soft capsules taken orally to prevent HAE attacks

      For more information, visit https://hae-rapide.com/, https://hae-rapide.us/ or https://clinicaltrials.gov/ct2/show/NCT04618211

      click here to read our Expanded Access Policy